Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02433171 · ClinicalTrials.gov registry record
Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery
A clinical trial, sponsored by Yale University.
- Terminated
- Registry status
- 8
- Enrollment target
NCT02433171 is a clinical trial that was terminated before completion, run by Yale University. The registered enrollment target is 8 participants.
The verdict
NCT02433171 was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
The goal of this protocol is to evaluate the potential of PET imaging of amino acid transport and microglial activation to improve the differentiation of tumor recurrence and radiation necrosis in patients with brain metastases after treatment with stereotactic radiosurgery (SRS) who have re-growing lesions. These state-of-the-art imaging tools will be used in combination with standard magnetic resonance imaging (MRI), MR spectroscopy (MRS) and FDG-PET (fluorodeoxyglucose).
Interventions
- PROCEDURE Standard of Care FDG-PET Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-06-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02433171
The ClinicalTrials.gov registry entry for NCT02433171 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Standard of Care FDG-PET Imaging is the first listed.
NCT02433171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02433171 about?
NCT02433171 is a clinical study titled "Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery". The goal of this protocol is to evaluate the potential of PET imaging of amino acid transport and microglial activation to improve the differentiation of tumor recurrence and radiation necrosis in patients with brain metastases after treatment with stereotactic radiosurgery (SRS) who have re-growing...
What is the current status of trial NCT02433171?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2015-01. Estimated completion is 2017-06-27.
What interventions are being tested in trial NCT02433171?
The interventions under investigation include: Standard of Care FDG-PET Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT02433171?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.